Metsera Declares Novo Nordisk’s $10 Billion Offer Superior to Pfizer’s Bid
Metsera, a company specializing in obesity treatments, announced that it has received a revised acquisition proposal from Novo Nordisk. After reviewing the offer with its counsel and advisors, Metsera’s Board of Directors determined that the new proposal is superior to the existing bid from Pfizer.
Novo Nordisk’s amended offer values Metsera at up to $86.20 per share, or approximately $10 billion in total. This is higher than Pfizer’s revised proposal, which valued Metsera at up to $70 per share, or about $8.1 billion.
According to the merger agreement with Pfizer, Metsera and Pfizer may engage in negotiations about possible changes for two business days. During this time, the agreement with Pfizer remains in effect, and Metsera shareholders do not need to take any action.
It means Metsera’s board believes the Novo Nordisk proposal is better for its shareholders than Pfizer’s current offer.
No, shareholders do not need to take any action at this time.
Yes, under the merger agreement, Metsera and Pfizer can negotiate possible changes for two business days.
WSJ
CNBC
GlobeNewsWire
Reuters
Investors Business Daily
Proactive Investors
CNBC Television
Invezz
Benzinga
Barrons
Market Watch
CNBC International TV